Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth
Hintz H, Snyder K, Wu J, Hullsiek R, Dahlvang J, Hart G, Walcheck B, LeBeau A. Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth. Cancer Immunology Research 2021, 9: 1270-1282. PMID: 34452926, PMCID: PMC9119026, DOI: 10.1158/2326-6066.cir-21-0178.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAntibody-dependent cell-mediated cytotoxicityCastration-resistant prostate cancerEffector-target cell ratioNatural killer cellsCell-mediated cytotoxicityIsotype control antibodyNK-92 cellsCombination of mAbsNK-92MI cellsProstate cancer growthCalcium signal transducer 2NK cell linesTumor-associated calcium signal transducer 2Fibroblast activation protein alphaOverall survivalNK cellsCell activation mechanismsImmunotherapy responseKiller cellsNK-92MICombination therapyPrior sensitizationControl antibodyProstate cancer